Startups · AI

Research Scientist I/II, Bioanalytical Sciences & Assay Development

Iambic Therapeutics · San Diego HQ · On-site

← All jobs
About Iambic Therapeutics

Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need. Backed by Sequoia.

About the role

We are seeking a highly motivated Research Scientist, Bioanalytical Sciences & Assay Development to join our drug discovery team. This scientist will develop and implement mass spectrometry-based assays and bioanalytical workflows supporting Hit Identification (HitID), ADME/DMPK characterization, and physicochemical property assessment.

More about this role

JOB SUMMARY

We are seeking a highly motivated Research Scientist, Bioanalytical Sciences & Assay Development to join our drug discovery team. This scientist will develop and implement mass spectrometry-based assays and bioanalytical workflows supporting Hit Identification (HitID), ADME/DMPK characterization, and physicochemical property assessment. A key focus will be the development and application of MS-based screening approaches for HitID, including Affinity Selection Mass Spectrometry (ASMS) and other MS-based capabilities.

The ideal candidate will have a strong foundation in bioanalytical science, mass spectrometry, and assay development, with the ability to develop robust and scalable assays for small-molecule drug discovery. This scientist will work at the interface of experimental science, automation, and AI-driven molecular design, generating high-quality data that inform compound optimization and enable rapid design–make–test–learn cycles. This position will be based in our San Diego Headquarters.

KEY RESPONSIBILITIES

Develop and implement MS-based assays and screening workflows for HitID, including ASMS and other MS-based approaches.

Develop fit-for-purpose...

Read the full posting on Iambic Therapeutics's site ↗

Science

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.